Check for updates

RESEARCH ARTICLE

REVISED *In silico* analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus [version 2; peer review: 2 approved]

Jaspreet Jain^{1*}, Anchala Kumari^{2,3*}, Pallavi Somvanshi^{id}³, Abhinav Grover², Somnath Pai⁴, Sujatha Sunil^{id}¹

¹Vector Borne Disease group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India

²School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

³Department of Biotechnology, Teri University, New Delhi, India

⁴Department of Virology and Immunology, Amity University, Uttar Pradesh, India

* Equal contributors

V2 First published: 30 Aug 2017, 6:1601
<https://doi.org/10.12688/f1000research.12301.1>

Latest published: 08 Dec 2017, 6:1601
<https://doi.org/10.12688/f1000research.12301.2>

Abstract

Background: Chikungunya fever presents as a high-grade fever during its acute febrile phase and can be prolonged for months as chronic arthritis in affected individuals. Currently, there are no effective drugs or vaccines against this virus. The present study was undertaken to evaluate protein-ligand interactions of all chikungunya virus (CHIKV) proteins with natural compounds from a MolBase library in order to identify potential inhibitors of CHIKV.

Methods: Virtual screening of the natural compound library against four non-structural and five structural proteins of CHIKV was performed. Homology models of the viral proteins with unknown structures were created and energy minimized by molecular dynamic simulations. Molecular docking was performed to identify the potential inhibitors for CHIKV. The absorption, distribution, metabolism and excretion (ADME) toxicity parameters for the potential inhibitors were predicted for further prioritization of the compounds.

Results: Our analysis predicted three compounds, Catechin-5-O-gallate, Rosmarinic acid and Arjunenin, to interact with CHIKV proteins; two (Catechin-5-O-gallate and Rosmarinic acid) with capsid protein, and one (Arjunenin) with the E3.

Conclusion: The compounds identified show promise as potential antivirals, but further *in vitro* studies are required to test their efficacy against CHIKV.

Open Peer Review

Approval Status

	1	2
version 2 (revision) 08 Dec 2017	view

version 1 30 Aug 2017	view	view

1. **Soma Chattopadhyay**, Institute of Life Sciences, (Autonomous Institute of Department of Biotechnology, Government of India), Bhubaneswar, India
2. **Debasis Nayak**, Indian Institute of Technology Indore, Indore, India
Parimal Kar, Indian Institute of Technology Indore, Indore, India

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

In silico analysis, Chikungunya virus, natural compounds, CHIKV E3 protein, CHIKV Capsid protein, Docking, ADME, Ligand-Protein Interaction

This article is included in the **Emerging Diseases and Outbreaks** gateway.

This article is included in the **Chemical Information Science** gateway.

This article is included in the **Neglected Tropical Diseases** collection.

Corresponding author: Sujatha Sunil (sujatha@icgeb.res.in)

Author roles: **Jain J:** Conceptualization, Formal Analysis, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Kumari A:** Formal Analysis, Investigation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Somvanshi P:** Resources, Software; **Grover A:** Resources, Software, Supervision; **Pai S:** Supervision; **Sunil S:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Jain J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Jain J, Kumari A, Somvanshi P *et al.* ***In silico* analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus [version 2; peer review: 2 approved]** F1000Research 2017, 6:1601 <https://doi.org/10.12688/f1000research.12301.2>

First published: 30 Aug 2017, 6:1601 <https://doi.org/10.12688/f1000research.12301.1>

REVISED Amendments from Version 1

In this revised version of the manuscript, we have incorporated all the changes suggested by the reviewers. **Figure 4** has been changed along with its figure legend.

See referee reports

Introduction

Chikungunya virus (CHIKV) is an alphavirus belonging to the *Togaviridae* family¹. These are small, spherical, enveloped viruses that constitute a positive-sense single-stranded RNA genome of approximately 11.8 kb^{2,3}. The genome encodes for five structural proteins (Capsid (CP), E3, E2, 6K and E1) and four nonstructural polyproteins (nsP1-4). Recently, CHIKV has spread widely and is the cause of a febrile illness of global concern with the potential to affect millions of people worldwide. As of 2016, Chikungunya fever has been identified in nearly 60 countries ([WHO Chikungunya report](#); accessed 3 August 2017). Some recent outbreaks have been observed in Africa, Asia, Europe, islands in the Indian and Pacific Oceans, and recently on the Caribbean islands in America⁴⁻⁷. CHIKV infection is characterized by severe debilitating muscle and joint pain, and polyarthralgia, which persists for about 3–12 months and could last up to 1–3 years⁸⁻¹⁰. In some instances, severe CHIKV infection may cause neurological disorders and ocular manifestations¹¹⁻¹³. Other symptoms include headache, myalgia, vomiting and rash^{14,15}. Until now, there is no effective antiviral treatment, or vaccine, is commercially available for the treatment of CHIKV, and patients are treated symptomatically.

Studies on antivirals for chikungunya generally target the replication machinery (nsP2 and nsP3 proteins)¹⁶⁻²¹ and surface receptors responsible for the binding of the virus during endocytosis (E1 and E2 proteins)^{19,21}. Recent studies have shown that CHIKV is able to affect the central nervous system (CNS) like new world alphaviruses, such as Venezuelan equine encephalitis virus and Eastern equine encephalitis virus. Thus, it is important to evaluate CHIKV as a transition between new and old world viruses. Old world viruses use nsP2 to inhibit transcription of host proteins, whereas new world viruses have developed an alternative mechanism of transcription inhibition that is mainly determined by their CP protein²². Hence, CP could be an important target protein for potential antivirals. Up until now, the other structural protein of CHIKV, E3, has not been evaluated as a target for antivirals till now. E3 is the only protein in the CHIKV genome with a secretory signal.

Alphavirus CP is a multifunctional protein known to act as serine protease for self-cleavage and viral genomic RNA binding. It is also known to bind to other CP molecules during nucleocapsid formation, and interact with viral spike proteins during virion formation and budding²³. CHIKV CP is 261 amino acids long protein and has a molecular weight of approximately 30kDa, and contains two major domains. N-terminal domain is positively charged and is involved in non-specific RNA binding, while the C-terminal domain regulates globular protease and acts as a binding site for the spike protein²⁴. In addition, nuclear import export signals

are present on the CP's amino acid terminal, forming immobile aggregations with nsP3 and E2 proteins of CHIKV²⁵.

The structural protein E3 is approximately 6KDa, and is found not to be associated with the mature virion². It serves as the signal sequence for the translocation of E3-E2-6K-E1 polyprotein into the endoplasmic reticulum, working in a clade-specific manner, and its cleavage from E2 is essential for virus maturation²⁶. E3 also mediates pH protection of E1 during virus biogenesis via interactions strongly dependent on Y47 at the E3-E3 interface²⁷.

In the present study, we performed an *in silico* analysis of protein-ligand interactions of all CHIKV proteins using a natural compound library from MolBase to predict potential antiviral compounds for CHIKV infection. Our analysis predicted three compounds that interacted with CHIKV proteins (two with the E3 protein, and one with the CP), making them potential antiviral candidates against CHIKV.

Methods

Target identification and homology modeling

Structures of CHIKV proteins E1, E2, E3, nsP2 and nsP3 were downloaded directly from RCSB Protein Data Bank (PDB). For the rest of the CHIKV proteins, CP, 6K, nsP1 and nsP4, whose structures are unavailable, CHIKV sequences present in NCBI, belonging to ECSA (East/Central/South Africa) genotype were downloaded. These sequences were utilized to form a consensus sequence with MEGA 6²⁸ using clustalW pairwise multiple alignment algorithm with all parameters set at default. Using these consensus sequences, homologous proteins from the PDB were identified using Protein BLAST²⁹ where the algorithm parameters were as follows: Max target sequences=100, Expect threshold=10 using BLOSUM62 scoring parameters, Gap cost=Existence:11 & Extension:1 with conditional compositional score matrix adjustment. The suitable templates for nsP1 and CP with highest query coverage, sequence identity and lowest E-value were selected for homology modeling. For proteins 6K and nsP4, no templates were available, and thus these structures were created using threading and looping method (see next section).

The template and target sequences of all CHIKV proteins were then aligned using CLUSTALW³⁰. MODELLER (version 9.16) was used to generate homology models³¹. Further, the homology model having the lowest MODELLER objective function (molpdf) or DOPE or SOAP assessment scores, or the one having highest GA341 score was selected as the best model structures and were further utilized for model validation. Non-structural protein, nsP4, and the small accessory peptide of structural protein 6K did not have any template in PDB; therefore a threading and looping approach was implemented for them using LOMETS (Local Meta Threading Server)³². Both online server and standalone program present as a module of I-TASSER Suite version 5.1, which provides 3D models by combining alignment scores of template to target of 9 different threading programs (FFAS-3D, HHsearch, MUSTER, pGenTHREADER, PPAS, PRC, PROSPECT2, SP3, and SPARKS-X). All parameters were set as default. All structural and nonstructural CHIKV protein sequences were selected as potential drug targets.

Validation of homology modeled structures

Generated models were validated using MolProbity-(v4.3.1)³³. Ramachandran plot analysis was performed for the best protein models by analyzing the phi (Φ) and psi (ψ) torsion angles. To check reliability of the modeled structures, the root mean square deviation (RMSD) was calculated by superimposing it on template protein structure using PyMOL (v1.7.0.0) visualization software³⁴. Consistency between templates and the modeled structures were assessed by ProSA-web³⁵ (online server), a statistical analysis tool of all the proteins structures available at RCSB PDB. Here, a statistical average is obtained over the known structures with the help of combined potentials of mean force from the PDB database.

Molecular dynamic simulations

Stability of the domain regions of CHIKV protein structures was examined by molecular dynamics (MD) simulation using GROMACS (version 5.0) software package³⁶. Optimized Potential for Liquid Simulations All-Atom³⁷ force field was used to energy minimize the structures. Through this energy minimization, the high-energy intramolecular interactions were discarded. In order to avoid the steric clashes, overall geometry and atomic charges were also optimized. The proteins were kept at the center of the rectangular box, which was filled with SPC water model system to create the same environmental behavior of the molecules. All the atoms of the protein and the boundary of the rectangular box were separated by a minimum distance of 10 Å. 0.01M NaCl was used as a solvent exposure.

The system was further energy minimized without any restraints for 50,000-time steps; the steepest descent having step size of 0.01 ps. Then the system was equilibrated to reach a stable temperature by conducting NVT ensemble. Pressure was further equilibrated by NPT ensemble performance. The long-range electrostatic interactions were calculated by using particle mesh Ewald³⁸ method with a cut-off of 0.9 nm for Vander Waals interactions. All the bonds were constrained by LINCS³⁹, where only the water molecule moves to equilibrate with respect to protein structure keeping protein molecule as static. To couple the system Berendsen thermostat (V-rescale) and Parrinello-Rahman barostat were utilized to maintain the constant temperature (300 K) and pressure (1 bar). Further MD analysis was performed to observe structural changes and dynamic behavior of the protein by calculating RMSD, radius of gyration and root mean square fluctuation (RMSF) along with changes in temperature, pressure, density and total energy.

Virtual screening and molecular docking

Simulated computational models of CHIKV proteins were prepared and their binding sites were predicted using SiteMap (Version 2.3, 2009, Schrödinger, LLC, New York, USA). These were then used to perform molecular docking. The protein preparation wizard was used to prepare CHIKV proteins and a natural remedies library from MolBase database was prepared using the LigPrep module⁴⁰. Virtual screening of modeled proteins against a natural remedy library from MolBase was done by using GLIDE module in an Extra Precision (XP) mode (Version 5.5, 2009, Schrödinger, LLC). It produces the minimal ranks of inappropriate

poses and determines the appropriate binding energy of the three dimensional (3D) structure of the protein along with a ligand^{41,42}.

Analysis and output visualization of drug target and protein

After the completion of molecular docking, the docked poses were listed depending upon the respective docking scores. Glide Score (obtained using GLIDE Module of Schrödinger Software Suite 9.0) was used as an empirical scoring function to predict free energy for ligands binding to the receptor. The structure showing minimum binding energy was filtered and subjected for further analysis. The 3D conformation ligand receptor was analyzed using PyMOL³⁴ and Chimera⁴³ v1.10.1 visualization software.

Absorption, distribution, metabolism and excretion (ADME) screening and toxicity analysis

Pharmacokinetics properties and percent human oral absorption values were further predicted for the potential lead molecules using QikProp module (Version 3.2, 2009, Schrödinger, LLC)⁴⁴. Both the physically remarkable descriptors and pharmaceutically admissible properties were predicted for neutralized ligands by QikProp. The program predicts 44 different properties, including log P (octanol/water), % human oral absorption in intestine (QP%) and predicted IC₅₀ value for blockage of HERG K⁺ channels (log HERG). The Lipinski's rule of five⁴⁵, an important criteria for oral absorption, was evaluated for the acceptability of the compounds. In addition, admetSAR⁴⁶ v1.0 was used to calculate various attributes of the drugs, including the blood brain barrier (BBB), human intestinal absorption, Caco-2 permeable, aqueous solubility, P-gp substrate and inhibitor, CYP450 substrate and inhibitor, CYP IP, ROCT, HERG inhibition, and toxicity parameters. For Lipinski score calculations, the ligand in SMILE format was uploaded to QikProp. The physicochemical properties and Lipinski Rule of Five were also analyzed by PERL script, "CalculatePhysicochemicalProperties.pl" of MayaChemTools⁴⁷.

Ligand-protein interaction studies

The protein-ligand complex interaction at the atomic level was analyzed using Maestro 11.0 (LLC Schrodinger 2016)⁴⁸ and LigPlot+⁴⁹ v1.4.5. The protein and the docked ligand were merged together and uploaded to Maestro Suite vMaestro 11. Further, the "Ligand Interaction Diagram" option was selected to draw the protein-ligand binding interactions in the 2D visualization workspace.

Results

In silico protein preparation, homology modeling and validation

CHIKV consists of four nonstructural proteins (nsP1-nsP4), three structural proteins (E1-E3), along with two sub-pro regions 6K and CP, which makes a part of structural protein unit (Figure 1). Structures of CHIKV proteins E1, E2, E3, nsP2 and nsP3 were downloaded directly from PDB (Figure 2a), and for other CHIKV proteins (CP, 6K, nsP1 and nsP4) homology modeling and threading and looping methods were utilized to predict their structures. For proteins with templates available, homology modeling was done with five models for every protein created based on sequence similarity using different model generation tools (MODELLER and LOMET), and validated by their internal scoring functions (molpdf,

Figure 1. Organization of chikungunya virus genome. The genome consists of two open reading frames (ORFs) separated by an untranslated junction (J). The first ORF encodes for a polyprotein and acts as a precursor of the non-structural proteins (nsP1, nsP2, nsP3 and nsP4). The second ORF encodes the structural proteins (Capsid, E3, E2, 6K and E1). The genome has 5' cap and 3' poly A tail.

Figure 2. Structures of chikungunya virus proteins. (A) X-Ray structures of nsP2, E3, nsP3, E1 and E2. (B) Homology modelled structures of nsP1, Capsid, nsP4 and 6K.

DOPE, SOAP and GA341 scores). Further, ProSA Z-score for all modelled structures were calculated to analyze the quality of models based on the C α positions. Individual validation and ProSA Z scores for top ranked models are given in Table 1 and their structures are given in Figure 2b. The top ranked models were also analyzed by Ramachandran plot (Figure 3). The Ramachandran plot shows the distribution of phi (ϕ) and psi (ψ) angles for each amino

acid residues of the modeled structures. The respective percentages of the favored and allowed regions for all the residues of all those validated are also shown in Table 1.

Molecular dynamic simulation and analysis

Molecular dynamic simulations were employed to analyze the protein structure-function complexities, such as structural stability,

Table 1. Results for model generation of chikungunya virus (CHIKV) proteins (E3, Capsid, 6K, nsP1 and nsP4). This table includes validation using various simulation scores for the best ranked models for structural and nonstructural proteins of CHIKV.

CHIKV Proteins	TEMPLATE Details		BLAST Results				MODELLAR Results			ProSA Results		Ramachandran plot analysis		
	PDB IDs of the Template	Chain ID	Max Score	Total Score	Query cover	E-Value	Identity	molpdf	DOPE Score	GA341 Score	RMSD (Å)	ProSA Z-Score	Favoured regions (aa residues) (%)	Allowed regions (aa residues) (%)
nsP1	1FW5	A	39.7	39.7	3%	2.00E-04	89%	2441.80	-16203.94	0.70	0.35	0.89	516/533 (96.8%)	532/533 (99.8%)
nsP4	Threading and Looping	-	-	-	-	-	-	-	-	-	0.68	3.04	584/609 (95.9%)	605/609 (99.3%)
Capsid	3J2W	I	315	315	57%	2.00E-110	99%	1253.26	-17861.93	1.00	0.11	-4.17	251/259 (96.9%)	258/259 (99.6%)
6K	Threading and Looping	-	-	-	-	-	-	-	-	-	0.68	-3.05	57/59 (96.6%)	59/59 (100%)

Figure 3. Ramachandran plot of chikungunya virus proteins obtained from MolProbity. (A) nsP1 and Capsid (homology modeling); **(B)** nsP4 and 6K (Threading/Looping).

conformational flexibility and folding. Domain regions of the structures (Table 2) were simulated for 20 ns. Moreover, various parameters, such as temperature, pressure, density and total energy, were calculated to check the stability of these structures along with steric properties. Further, RMSD values for the backbone atoms of proteins were plotted against time of MD simulations. Average RMSD during the simulations was 22.93. Radius of gyration on the other hand also supports the stability and compactness of the proteins. The RMSF with respect to each residue depicts the flexibility of the proteins. Average RMSF during the simulations was 1.45. The RMSD, radius of gyration and RMSF plots for all CHIKV proteins

are shown in Figure 4A–C. The resulting graphs contributed to protein modeling, as they show a constant RMSD deviation throughout the 20ns simulation except for a small deviation in E2 after 14ns. Depending upon these simulation parameters, the proteins showed conformational stability.

Molecular docking

Drug discovery relies heavily on molecular docking to understand the interactions between ligand/inhibitor and target protein⁵⁰. In this study, we resorted to the docking of available protein structures (wherever applicable), as well validated, refined and simulated

modeled proteins to screen against a natural remedy library from MolBase. The binding sites of all protein structures were predicted by SiteMap. The predicted binding pockets were further validated using Glide in XP mode. Top ten ligand/compounds having docking score (Glide Score) above -4, glide energy of $-20 \text{ kcal mol}^{-1}$ and potential energy of a considerable range were considered for the next level of screening. The combined results of all the docked ligand along with the glide energy and potential energy have been provided in Table 3. Of these, two

ligands, (1,3,6, -Trigalloyl- β -D-Glucose and Quercetin-3-rutinoside (Compound ID 164 and 153) were found to interact with all the proteins and were discarded from further analysis.

For the non-structural proteins, the top ligands included Rebaudioside A and Withanoside IV (Compound ID 149 and 179) for nsP1; Stevioside, Bacopaside II and Jujubogenin isomer of bacopasaponin C (Compound ID 161, 26 and 113) for nsP2; Chebulinic acid and Corilagin (Compound ID 44 and 47) for nsP3; Rebaudioside A and Stevioside (Compound ID 149 and 161) for nsP4. For structural proteins, Catechin-5-O-gallate, Rosmarinic acid and Agnuside (Compound ID 42, 151 and 18) for CP; Bacopaside II, Mangiferin and Arjungenin, (Compound ID 26, 122 and 12) for E3; (Rebaudioside A, Tribulosin and Asiaticoside (Compound ID 149, 165 and 17) for E2; Arjunetin and Stevioside (Compound ID 10 and 161) for 6K; Chebulinic acid, Stevioside and Asiaticoside (Compound ID 44, 161 and 17) for E1. Top four docked poses of the modeled proteins and the small molecules having lowest docking score are shown in Figure 5 (ligand wise).

Unique ligand-protein partners were taken forward for ADME and toxicity analysis. In case of nonstructural proteins, these ligand-protein pairs were Withanoside IV (Compound ID 179)-nsP1, Jujubogenin isomer of bacopasaponin C (Compound ID 113)-nsP2 and Corilagin (Compound ID 47)-nsP3. In case of structural proteins, these pairs were Catechin-5-O-gallate (Compound ID 42), Rosmarinic acid (Compound ID 151) and Agnuside (Compound ID 18) against CP, Mangiferin (Compound ID 122) and Arjungenin (Compound ID 12) against E3, Tribulosin (Compound ID 165) against E2, and Arjunetin (Compound ID 10) against 6K.

Table 2. Domain regions/ amino acid residues of chikungunya virus (CHIKV) modelled proteins used for molecular docking experiments.

CHIKV	Domain region of protein (residues)
nsP1	245-260
nsP2	28-259
nsP3	28-259
nsP4	2-49
Capsid	113-261
E3	1-64
E2	113-261
6K	1-61
E1	113-261

Figure 4. Molecular dynamics profiles of the chikungunya virus (CHIKV) proteins tertiary domain structure optimization. (A) root mean square deviation (RMSD), **(B)** Radius of Gyration, and **(C)** root mean square fluctuation (RMSF). **A–C** graphs are vs Time, and **F** vs Atoms. Each set shows the graph for both Non-structural (upper) and Structural (lower) CHIKV proteins. Non-structural Protein: nsP1 (green), nsP2 (blue), nsP3 (yellow) and nsP4 (red); Structural Proteins: Capsid (orange), E3 (mustard), E2 (purple), 6K (cyan) and E1 (pink).

Table 3. Combined results of top four docked ligand with chikungunya virus proteins along with the glide score, glide energy and potential energy.

NON STRUCTURAL PROTEIN						
Comp ID	Compound name	Chemical name	Molecular formula	Glide score	Glide energy	Potential energy
nsp1						
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-7.54	-43.61	151.40
149	Rebaudioside A	13-Hydroxy-16-kauren-19-oic acid; entform, 13-O-[β-D-Glucopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-β-D-glucopyranoside], β-D-g	C44 H70 O23	-6.94	-46.23	622.16
153	Rutin	Quercetin-3-rutinoside	C27 H30 O16	-6.52	-38.91	259.01
179	Withanoside IV	1,3,27-Trihydroxywitha-5,24-dienolide; (1α,3β)-form, 3-O-[β-D-Glucopyranosyl-(1->6)-β-D-glucopyranoside]	C40 H62 O15	-5.49	-41.46	552.81
nsp2						
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-9.47	-64.32	151.40
161	Stevioside	13-Hydroxy-16-kauren-19-oic acid; ent-form, 13-O-[β-D-Glucopyranosyl-(1->2)-α-D-glucopyranoside], β-D-glucopyranosyl ester	C38 H60 O18	-8.66	-45.72	548.61
26	Bacopaside II	Pseudojубogenin; 3-O-[α-L-Arabinofuranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-β-D-glucopyranoside]	C47 H76 O18	-7.66	-50.36	955.71
113	Jубogenin isomer of bacopasaponin C	Jубogenin; 3-O-[α-L-Arabinofuranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-α-L-arabinopyranoside]	C46H74O17	-7.64	-44.88	879.85
nsp3						
44	Chebulinic acid	[(3s,3as,4s,7r,8r,10s,11r,17s)-3,15,16-trihydroxy-2,5,13-trioxo-10,17-bis[(3,4,5-trihydroxybenzoyl)oxy]-8-[[[(3,4,5-trihydroxybenzoyl)oxy)methyl]-2,3,3a,4,5,7,8,10,11,13-decahydro-7,11-methano[1,4,7]trioxacyclotridecino[11,10,9-de]chromen-4-yl]acetic acid	C41H32O27	-12.36	-82.33	451.70
47	Corilagin	1-O-Galloyl-3,6-(R)- hexahydroxydiphenoyl-β-Dglucopyranose	C27H22O18	-8.96	-56.60	232.70
153	Rutin	Quercetin-3-rutinoside	C27 H30 O16	-8.50	-55.75	259.01
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-8.17	-68.12	151.40
nsp4						
149	Rebaudioside A	13-Hydroxy-16-kauren-19-oic acid; entform, 13-O-[β-D-Glucopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-β-D-glucopyranoside], β-D-g	C44 H70 O23	-8.87	-55.61	622.16
153	Rutin	Quercetin-3-rutinoside	C27 H30 O16	-8.30	-51.12	259.01
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-8.27	-63.20	151.40
161	Stevioside	13-Hydroxy-16-kauren-19-oic acid; ent-form, 13-O-[β-D-Glucopyranosyl-(1->2)-α-D-glucopyranoside], β-D-glucopyranosyl ester	C38 H60 O18	-8.01	-50.24	548.61

STRUCTURAL PROTEIN						
Comp ID	Compound Name	Chemical Name	Molecular Formula	Glide Score	Glide Energy	Potential
Capsid						
42	Catechin-5-O-gallate	3,3',4',5,7-Pentahydroxyflavan; (2R,3S)-form, 5-O-(3,4,5-Trihydroxybenzoyl)	C22 H18 O11	-6.26	-38.05	96.39
151	Rosmarinic acid	3-(3,4-Dihydroxyphenyl)-2-hydroxypropanoic acid; (R)-form, 2-O-(3,4-Dihydroxy-E-cinnamoyl)	C18H16O8	-6.12	-28.87	53.75
18	Agnuside	[(1S,4aR,5S,7aS)-5-hydroxy-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-7-yl)methyl 4-hydroxybenzoate	C22H26O11	-5.83	-40.81	188.75
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-5.41	-43.32	151.40
E3						
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-6.77	-57.04	151.40
26	Bacopaside II	Pseudojubilogenin; 3-O-[α-L-Arabinofuranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-β-D-glucopyranoside	C47 H76 O18	-6.28	-46.22	955.71
122	Mangiferin	2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one	C19H18O11	-6.11	-38.93	198.08
12	Arjungenin	2,3,19,23-Tetrahydroxy-12-oleanen-28-oic acid; (2α,3β,19α)-form	C30H48O6	-6.02	-30.81	512.65
E2						
149	Rebaudioside A	13-Hydroxy-16-kauren-19-oic acid; entform, 13-O-[β-D-Glucopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-β-D-glucopyranoside], β-D-g	C44 H70 O23	-10.71	-62.53	622.16
165	Tribulosin	Spirostan-3-ol; (3β,5α,25S)-form, 3-O-[β-D-Xylopyranosyl-(1->2)-[β-D-xylopyranosyl-(1->3)]-β-D-glucopyranosyl-(1->4)]-α	C55H90O25	-10.07	-60.51	957.86
153	Rutin	Quercetin-3-rutinoside	C27 H30 O16	-8.64	-45.10	259.01
17	Asiaticoside	2,3,23-Trihydroxy-12-ursen-28-oic acid	C48 H78 O19	-8.50	-52.90	805.10
6K						
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-6.83	-50.95	151.40
10	Arjunetin	2,3,19-Trihydroxy-12-oleanen-28-oic acid; roxymethyl)oxan-2-yl] (4aS,6aR,6aS,6bR,10S,11S,12aS,14bR)-10,11-dihydroxy-12a-(hydroxymethyl)-2,2,6a,6b,9,9-	C36H58O10	-6.43	-36.56	543.12
161	Stevioside	13-Hydroxy-16-kauren-19-oic acid; ent-form, 13-O-[β-D-Glucopyranosyl-(1->2)-α-D-glucopyranoside], β-D-glucopyranosyl ester	C38 H60 O18	-6.32	-39.69	548.61
153	Rutin	Quercetin-3-rutinoside	C27 H30 O16	-6.06	-40.84	259.01
E1						
44	Chebulinic acid	[(3s,3as,4s,7r,8r,10s,11r,17s)-3,15,16-trihydroxy-2,5,13-trioxo-10,17-bis[(3,4,5-trihydroxybenzoyl)oxy]-8-[(3,4,5-trihydroxybenzoyl)oxy]methyl)-2,3,3a,4,5,7,8,10,11,13-decahydro-7,11-methano[1,4,7]trioxacyclotridecino[11,10,9-de]chromen-4-yl]acetic acid	C41H32O27	-9.77	-62.87	451.70
164	1,3,6,-Trigalloyl-β-D-Glucose	1,3,6-Trigalloylglucose; β-D-Pyranose-form	C27H24O18	-8.48	-52.97	151.40
161	Stevioside	13-Hydroxy-16-kauren-19-oic acid; ent-form, 13-O-[β-D-Glucopyranosyl-(1->2)-α-D-glucopyranoside], β-D-glucopyranosyl ester	C38 H60 O18	-8.13	-40.94	548.61
17	Asiaticoside	2,3,23-Trihydroxy-12-ursen-28-oic acid	C48 H78 O19	-7.40	-50.53	805.10

Figure 5. Binding interaction with the potential lead compounds and their representative binding pocket conformation for the top four docked poses of all chikungunya virus proteins. Ligands are cyan sticks and receptors as pink ribbon/surface.

ADME analysis of all potential leads

ADME screening was performed for all the top hits. Here, 44 various physically remarkable descriptors⁵¹ and pharmaceutically admissible properties of the top four lead compounds for every CHIKV protein were calculated using QikPro-P (Table 4). The Lipinski's rule of five was further employed to evaluate oral

absorption along with ADME. Compounds violating more than 2 Lipinski's rule of 5 were discarded from further analysis.

Compounds Catechin-5-O-gallate (Compound ID 42), Rosmarinic acid (Compound ID 151) and Agnuside (Compound ID 18) against CP; Mangiferin (Compound ID 122) and Arjungenin

Table 4. QikProp analysis of physically remarkable descriptors and pharmaceutically admissible properties of unique ligand-protein pairs for chikungunya virus proteins.

	nsP1-179	nsP2-113	nsP3-47	Capsid-42	Capsid-151	Capsid-18	E3-122	E3-12	E2-165	6K-10	Range-95% Drug
MW	782.92	899.08	634.46	442.38	360.32	466.44	438.34	504.71	1151.30	650.85	130-725
SASA	1066.54	1137.97	803.26	677.81	614.80	741.92	631.99	706.02	1448.98	864.39	300-1000
FOSA	697.96	815.05	84.99	46.25	44.58	166.74	94.86	481.89	1000.45	581.88	0-750
FISA	337.60	316.73	569.51	353.44	362.96	311.82	374.00	212.11	448.53	277.78	7-330
PISA	30.98	6.20	148.76	278.11	207.26	263.36	163.13	12.02	0.00	4.73	0-450
MV	2162.23	2381.53	1529.97	1240.78	1082.52	1348.34	1145.40	1448.13	3078.06	1782.28	500-2000
PSA	245.37	236.31	322.65	194.44	171.59	185.93	216.29	118.93	337.67	170.47	7-200
donorHB	8	9	11	7	5	6	7	5	13	7	0-6
accptHB	24.10	26.05	17.85	9.45	7.00	16.35	13.75	8.80	40.60	15.60	(2-20)
Glob	0.76	0.76	0.80	0.82	0.83	0.80	0.84	0.88	0.71	0.82	0.75-0.95
QPPolrz	69.12	77.66	48.15	40.38	32.08	42.62	34.18	47.42	100.98	58.16	13-70 M
QPIlogPo/w	-0.20	0.31	-3.21	0.20	0.83	-1.13	-1.87	3.26	-2.92	1.43	(-2-6.5)
QPIlogS	-4.06	-4.46	-2.93	-3.52	-2.95	-2.75	-2.15	-4.63	-3.23	-4.60	(-6.5-0.5)
CIQPIlogS	-5.36	-6.49	-5.34	-5.15	-4.23	-2.94	-3.47	-5.66	-5.32	-5.83	(-6.5-/0.5)
QPIlogKhsa	-1.02	-0.89	-1.10	-0.38	-0.56	-1.12	-1.00	0.29	-2.39	-0.07	(-1.5-1.2)
QPIlogBB	-4.44	-4.20	-6.16	-3.45	-3.62	-3.44	-3.65	-1.70	-6.94	-2.84	(-3.0-1.2)
Metab	13	12	11	9	6	9	8	6	13	9	(1-8)
QPIlogHERG	-5.59	-5.48	-5.49	-5.71	-3.48	-6.10	-4.94	-1.78	-6.29	-4.43	Below -5
QPPCaco	6.23	9.83	0.04	4.41	0.91	10.94	2.81	24.44	0.55	23.00	<25 poor
QPPMDCK	2.04	3.35	0.01	1.41	0.32	3.76	0.87	11.39	0.15	8.39	<25 poor
QPIlogKp	-5.90	-5.61	-10.24	-6.19	-6.42	-5.19	-6.78	-4.71	-7.39	-5.57	(-8/-1)
RuleOf3	2	2	2	2	1	2	2	0	2	2	Max 3
PHOA	1.12	7.64	0.00	26.71	31.01	13.03	0.00	57.89	0.00	33.76	<25% is poor
RuleOf5	3	3	3	1	0	2	2	1	3	2	Max 4

(Compound ID 12) against E3; and Arjunetin (Compound ID 10) against 6K were studied further in greater detail for their toxicity.

Toxicity analysis

The efficacy and unexpected toxicity of a drug to penetrate biological barriers, such as the intestinal wall or BBB, were considered as a prime determinant of the compounds taken forwards for toxicity tests. CHIKV is an old world virus, but is now seen to affect the

CNS as well; therefore, compounds that were predicted to cross the BBB were also considered as potential antivirals. Of all the compounds considered for toxicity analysis using AdmetSAR, Arjunetin (Compound ID 10) was considered ineffective for oral consumption and is also carcinogenic. Also, Agnuside (Compound ID 18) and Mangiferin (Compound ID 122) were not considered as potential antivirals as they are predicted to have positive AMES toxicity (Table 5).

Table 5. AdmetSAR analysis for pharmacokinetics properties, percent human oral absorption values and toxicity determination of drugs/ligands that follow the Lipinski's rule of five and fulfill other QikProp requirements.

Absorption						
Parameter	18	42	151	10	12	122
BBB	-	-	+	+	+	-
Human intestinal absorption	+	+	+	-	+	+
P-glycoprotein substrate	S	S	S	NS	S	S
P-glycoprotein inhibitor	NI	NI	NI	NI	NI	NI
Renal organic cation transporter	NI	NI	NI	NI	NI	NI
Metabolism						
Parameter	18	42	151	10	12	122
CYP450 2C9 substrate	NS	NS	NS	NS	NS	NS
CYP450 2D6 substrate	NS	NS	NS	NS	NS	NS
CYP450 3A4 substrate	NS	NS	NS	NS	S	NS
CYP450 1A2inhibitor	NI	NI	NI	NS	NI	NI
CYP450 2C9 inhibitor	NI	NI	NI	NS	NI	NI
CYP450 2D6 inhibitor	NI	NI	NI	NS	NI	NI
CYP450 2C19 inhibitor	NI	NI	NI	NS	NI	NI
CYP450 3A4 inhibitor	NI	NI	NI	NS	NI	NI
CYP Inhibitory Promiscuity	Low	Low	Low	Low	Low	Low
Toxicity						
Parameter	18	42	151	10	12	122
Human Ether-a-go-go-related gene inhibition	WI	WI	WI	WI	WI	WI
AMES toxicity	AT	NAT	NAT	NAT	NAT	AT
Carcinogens	NC	NC	NC	C	NC	NC
Fish toxicity	HT	HT	HT	LT	HT	HT
Tetrahymena pyriformis toxicity	HT	HT	HT	LT	HT	HT
Honey bee toxicity	HT	HT	HT	HT	HT	HT
Biodegradation	NRB	NRB	NRB	RB	NRB	NRB
Acute oral toxicity	III	III	III	III	III	IV
Carcinogenicity (Three-class)	NR	NR	NR	NR	NR	NR

+: Positive; -: Negative; NS: Non-substrate; S: Substrate; NI: Non-inhibitor; I: Inhibitors; BBB: Blood-brain barrier; CYP450: Cytochrome P450; WI: Weak inhibition; NAT: Non AMES toxic; AT: AMES toxic; NC: Non carcinogens; C: Carcinogen; HT: High toxic; RB: Readily biodegradable; NRB: Not readily biodegradable; NR: Not-required.

The compounds that were judged to be potential antivirals were Catechin-5-O-gallate (Compound ID 42) and Rosmarinic acid (Compound ID 151) against CP and Arjungenin (Compound ID 12) against E3 structural protein of CHIKV. Thus, the ligand/drug-protein interaction was studied for these three compounds to understand their interaction pattern and strength of interaction with the protein for their role as potential antivirals against CHIKV (Table 5).

Ligand protein interaction

A ligand protein interaction study was done for validated protein structures as discussed earlier. CP residues (Peptidase S3 domain) were predicted to bind to Catechin-5-O-gallate and Rosmarinic acid (Compound IDs 42 and 151, respectively) and E3 residues (Endopeptidase domain) bind to Arjungenin (Compound ID 12). The top docking conformation of Catechin-5-O-gallate showed a predicted binding energy of -6.26 kcal mol⁻¹, whereas Rosmarinic acid and Arjungenin showed similar binding energy of -6.11 kcal mol⁻¹ and -6.01 kcal mol⁻¹, respectively. The binding energy (Glide Score) and the interaction energy (Potential, Vander Waals and Electrostatic) are shown in Table 3. The intermolecular hydrogen bonds and hydrophobic residues showing close contact between receptor proteins (CP and E3) and ligand (Compound ID 42, 151 and 12) are shown in Table 6 and Figure 6A–C, respectively.

The interaction result showed that most of the hydrogen bond donors are from the protein that bind to the acceptors on the

respective ligands. The compound Catechin-5-O-gallate (Compound ID 42) binds to Glu260 and Lys141 residues (HBond distance of 2.57 and 2.93 Å) of the CP protein and forms hydrophobic interactions with Asp161, His139, Val140 and Trp261 residues (Figure 7a). Further 2-D workspace revealed that when the ligand-protein interactions were observed both in the presence and absence of solvent the compound Catechin-5-O-gallate binds to the CP protein, HIS139 forms the hydrogen backbone; GLU259, GLU260, ASP161 form the hydrogen side chain. The ligand forms hydrophobic interactions with TRP261, VAL140, LYS141 (Figure 7b). We were unable to acquire the Ligplot for the interaction of Rosmarinic acid (Compound ID 151) with CP protein as the coordinates were undetectable; however, using 2-D workspace, we identified that Rosmarinic acid binds to the CP protein, TRP261 forms the hydrogen backbone; GLU260, LYS141 form the hydrogen side chain. The ligand forms hydrophobic interactions with HIS139, VAL140, GLU259, ASP161 (Figure 7b). The third compound Arjungenin (Compound ID 12), binds with Arg63 and Gln52 residues (HBond distance of 2.72 and 3.11 Å) of the E3 protein and Ser18, His60 and Ser58 residues are involved in hydrophobic interactions (Figure 7a). Its 2-D workspace revealed that SER18, GLN49 form the hydrogen backbone; GLN52, SER58, ARG63 form the hydrogen side chain. The ligand forms hydrophobic interactions with PRO5, GLN19, ALA53, HIS60 (Figure 7b). Overall docking and interaction results for the best three natural compounds have been compiled in Table 7.

Table 6. Intermolecular hydrogen bonds and hydrophobic residues showing close contact between receptor chikungunya virus proteins and ligand.

Compound	Interacting Residue	H Bond Distance (Å)	H Bond (D-H--A)	Hydrophobic Residues
Catechin-5-O-gallate	Capsid:Glu260:OE1 - UNK900:het O4	2.567	HOE1-H--O4	His139, Val140, Asp161, Glu259, Trp261
	Capsid:Lys141:N - UNK900:het O9	2.927	HN-H--O9	
Rosmarinic acid	Capsid:Trp261:O1 - UNK900:het H14	2.039	HO1-H--H14	His139, Val140, ASP161, Glu259
	Capsid:Trp261:O1 - UNK900:het H15	1.927	HO1-H--H15	
	Capsid:Lys141:2HZ - UNK900:het O8	2.375	2HNZ-H--O8	
	Capsid:Lys141:3HZ - UNK900:het O5	1.987	3HNZ-H--O5	
	Capsid:Glu260:OE1 - UNK900:het H4	1.712	HOE1-H--H4	
	Capsid:Glu260:OE1 - UNK900:het H5	1.658	HOE1-H--H5	
Arjungenin	E3:Arg63:HNE - UNK900:het O6	2.720	HNE-H--O6	Pro5, Ser18, Glu19, Gln49, Ala53, Ser58, His60
	E3:Arg63:HN2 - UNK900:het O2	2.707	HN2-H--O2	
	E3:Gln52:OE1 - UNK900:het O1	3.108	HOE1-H--O1

Figure 6. Hydrogen bonding interactions between ligand and chikungunya virus proteins. (A) Hydrogen bonding interaction between Catechin-5-O-gallate [CompID - 42] and capsid, binding affinity of - 6.26 kcal/mol was obtained. The zoomed region shows the receptor-binding pocket. Residues that form hydrogen bond interaction are Glu260 (Distance - 2.57 Å) and Lys 141 (Distance - 2.93 Å); His139, Val140, Asp161, Glu259 and Trp261 forms hydrophobic interaction. (B) Hydrogen bonding interaction between Rosmarinic acid [CompID - 151] and capsid, binding affinity of - 6.11 kcal/mol was obtained. The zoomed region shows the receptor-binding pocket. Residues that form hydrogen bond interaction are Glu260 (Distance - 1.71 and 1.66 Å), Trp261 (Distance - 2.04 and 1.93 Å) and Lys 141 (Distance - 2.37 and 1.99 Å); His139, Val140, Asp161 and Glu259 forms hydrophobic interaction. (C) Hydrogen bonding interaction between Arjungenin [CompID - 12] and E3, binding affinity of - 6.01 kcal/mol was obtained. The zoomed region shows the receptor-binding pocket. Residues that form hydrogen bond interaction are Gln52 (Distance - 3.11 Å) and Arg63 (Distance - 2.72 and 2.71 Å); Pro5, Ser18, Gln19, Gln49, Ala53, Ser58 and His60 forms hydrophobic interaction.

Figure 7. Intermolecular hydrogen bonding in 2D view. (A) LigPlot of Comp 42 (Capsid) and Comp 12 (E3). **(B)** Maestro ligand interaction diagram of Comp 42 and 151 (Capsid) and Comp 12 (E3).

Table 7. Overall docking and interaction results for best three natural compounds.

Comp ID	Compound Name	Interacting CHIKV protein	Docking Score	Binding Energy (Kcal/mol)	Number of H-bond interaction	Residues in molecular interaction	Hydrophobic Residues
42	Catechin-5-O-gallate	Capsid	-6.26	-38.05	2	Glu260, Lys141	Asp161, His139, Val140, Trp261
151	Rosmarinic acid	Capsid	-6.11	-28.87	6	Lys141, Glu260, Trp261	His139, Val140, ASP161, Glu259
12	Arjungenin	E3	-6.01	-30.81	2	Gln52, Arg63	Ser18, His60, Ser58

Discussion

Several drug candidates have been tested for their antiviral activity against CHIKV^{8,52,53}. Recent studies have employed chemical libraries to screen for drug candidates for chikungunya with limited success^{16,17}. Recent efforts for identifying natural compounds against alphavirus replication revealed 44 inhibitors that were effective against several alphaviruses, including CHIKV replicon and Sindbis virus. The study revealed that these compounds inhibited the early stages of viral replication¹⁹. Currently, hundreds of thousands of natural compounds are available that can be utilized for screening purposes for identifying novel drug targets. The present study was performed using virtual screening of a natural compound library from MolBase, which showed three compounds, namely, Catechin-5-O-gallate, Rosmarinic acid and Arjungenin, as promising potential antivirals against CHIKV proteins.

Previous studies have suggested that Catechin-5-O-gallate is the most important catechin in green tea, commonly known as epigallocatechin-3-gallate (EGCG). Other catechins are also found in green tea extract, such as epigallocatechin, epicatechingallate and epicatechin. The biological activity of EGCG is assumed to be contributed by the galloyl side chain⁵⁴. EGCG is known to have antiviral activities towards a variety of viruses. EGCG also inhibits the cell entry of several viruses, such as human immunodeficiency virus (HIV)^{55–57}, influenza virus⁵⁸ and hepatitis C virus (HCV)^{59–61}. Additionally, inhibitory effects of EGCG on viral transcription have been described for viruses like hepatitis B virus, adenoviruses, or herpes viruses⁶². In case of CHIKV, a recent study on EGCG showed inhibition of CHIKV transduction by blocking cell entry against env-pseudotyped lentiviral vectors, which inhibits CHIKV attachment⁶³.

Rosmarinic acid (RA), a phenolic compound found in various Labiatae herbs⁶⁴, possesses several properties, such as anti-inflammatory^{65,66} and antioxidative, as it reduces liver injury induced by *D-galactosamine*⁶⁷ and lipopolysaccharides⁶⁸. Besides

these, RA acts as a potent antiviral agent against Japanese encephalitis virus (JEV), another alphavirus closely related to CHIKV. The study indicated that RA reduced viral replication within the brain along with the secondary inflammation resulting from microglial activation. These observations suggested that RA exhibited efficient antiviral as well as anti-inflammatory activity against Japanese equine encephalitis virus infection and hence was able to reduce disease severity⁶⁶.

The compound Arjungenin, a popular triterpenoid isolated from *Terminalia arjuna* *T. chebula*, shows inhibitory effects on HIV-1 Protease^{69,70}. Arjungenin has been previously used for a wide range of activities that includes anti-inflammatory, anti-microbial, anti-cancer and even anti-viral⁷¹, but no work has been done on this particular natural compound to date.

Conclusion

Treatment of chikungunya includes antipyretic drugs during the febrile stage and depends heavily on symptomatic relief during the chronic arthritic phase. Our present study has identified natural compounds that may be antiviral and might be good candidates as drugs for chikungunya treatment. Further *in vitro* validation is required for these compounds to provide insights into their mode of action against the different stages of chikungunya infection.

Data availability

All source data relating to this article can be found in [Supplementary File 1](#).

Competing interests

No competing interests were disclosed.

Grant information

The authors declare that no grants were involved in supporting this work.

Supplementary material

Supplementary File 1: Structures of CHIKV proteins (E1, E2, E3, nsP2 and nsP3) downloaded from PDB; sequences of the unknown structures found in NCBI (CP, 6K, nsP1 and nsP4); the homologous proteins identified for the unknown structure proteins in PDB and modeled structures using these template structures; protein structures prepared by threading and looping methods; the natural remedy library from MolBase and Ligand-protein docked structures.

[Click here to access the data.](#)

References

1. Strauss EG, Strauss JH: **Structure and replication of the alphavirus genome. The Togaviridae and Flaviviridae.** Springer. 1986; 35–90.
[Publisher Full Text](#)
2. Simizu B, Yamamoto K, Hashimoto K, *et al.*: **Structural proteins of Chikungunya virus.** *J Virol.* 1984; **51**(1): 254–8.
[PubMed Abstract](#) | [Free Full Text](#)
3. Fauquet CM, Mayo MA, Maniloff J, *et al.*: **Virus taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses.** Academic Press, 2005.
[Reference Source](#)
4. Ravi V: **Re-emergence of chikungunya virus in India.** *Indian J Med Microbiol.* 2006; **24**(2): 83–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Powers AM, Logue CH: **Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus.** *J Gen Virol.* 2007; **88**(Pt 9): 2363–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Renault P, Solet JL, Sissoko D, *et al.*: **A major epidemic of chikungunya virus infection on Reunion Island, France, 2005–2006.** *Am J Trop Med Hyg.* 2007; **77**(4): 727–31.
[PubMed Abstract](#)
7. Staples JE, Breiman RF, Powers AM: **Chikungunya fever: an epidemiological review of a re-emerging infectious disease.** *Clin Infect Dis.* 2009; **49**(6): 942–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Brighton SW, Prozesky OW, de la Harpe AL: **Chikungunya virus infection. A retrospective study of 107 cases.** *S Afr Med J.* 1983; **63**(9): 313–5.
[PubMed Abstract](#)
9. Lakshmi V, Neeraja M, Subbalaxmi MV, *et al.*: **Clinical features and molecular diagnosis of Chikungunya fever from South India.** *Clin Infect Dis.* 2008; **46**(9): 1436–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Londhey V, Agrawal S, Vaidya N, *et al.*: **Dengue and Chikungunya Virus Co-infections: The Inside Story.** *J Assoc Physicians India.* 2016; **64**(3): 36–40.
[PubMed Abstract](#)
11. Wadia R: **A neurotropic virus (chikungunya) and a neuropathic amino acid (homocysteine).** *Ann Indian Acad Neurol.* 2007; **10**(4): 198.
[Reference Source](#)
12. Taraphdar D, Sarkar A, Mukhopadhyay BB, *et al.*: **Rapid spread of chikungunya virus following its resurgence during 2006 in West Bengal, India.** *Trans R Soc Trop Med Hyg.* 2012; **106**(3): 160–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Mahendradas P, Avadhani K, Shetty R: **Chikungunya and the eye: a review.** *J Ophthalmic Inflamm Infect.* 2013; **3**(1): 35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Taubitz W, Cramer JP, Kapaun A, *et al.*: **Chikungunya fever in travelers: clinical presentation and course.** *Clin Infect Dis.* 2007; **45**(1): e1–e4.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Jain J, Nayak K, Tanwar N, *et al.*: **Clinical, Serological and Virological analysis of 572 chikungunya patients during the years 2010–2013 from India.** *Clin Infect Dis.* 2017; **65**(1): 133–140.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Bassetto M, De Burghgraeve T, Delang L, *et al.*: **Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus.** *Antiviral Res.* 2013; **98**(1): 12–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Pohjala L, Utt A, Varjak M, *et al.*: **Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays.** *PLoS One.* 2011; **6**(12): e28923.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Oliveira AF, Teixeira RR, Oliveira AS, *et al.*: **Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses.** *Molecules.* 2017; **22**(3): pii: E505.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Kaur P, Chu JJ: **Chikungunya virus: an update on antiviral development and challenges.** *Drug Discov Today.* 2013; **18**(19–20): 969–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Agarwal T, Asthana S, Bissoyi A, *et al.*: **Molecular modeling and docking study to elucidate novel chikungunya virus nsP2 protease inhibitors.** *Indian J Pharm Sci.* 2015; **77**(4): 453–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Lani R, Hassandarvish P, Chiam CW, *et al.*: **Antiviral activity of silymarin against chikungunya virus.** *Sci Rep.* 2015; **5**: 11421.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Garmashova N, Gorchakov R, Volkova E, *et al.*: **The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff.** *J Virol.* 2007; **81**(5): 2472–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Choi HK, Tong L, Minor W, *et al.*: **Structure of Sindbis virus core protein reveals a chymotrypsin-like serine proteinase and the organization of the virion.** *Nature.* 1991; **354**(6348): 37–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hong EM, Perera R, Kuhn RJ: **Alphavirus capsid protein helix I controls a checkpoint in nucleocapsid core assembly.** *J Virol.* 2006; **80**(18): 8848–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Thomas S, Rai J, John L, *et al.*: **Chikungunya virus capsid protein contains nuclear import and export signals.** *J Virol.* 2013; **10**(1): 269.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Snyder AJ, Mukhopadhyay S: **The alphavirus E3 glycoprotein functions in a clade-specific manner.** *J Virol.* 2012; **86**(24): 13609–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Uchime O, Fields W, Kielian M: **The role of E3 in pH protection during alphavirus assembly and exit.** *J Virol.* 2013; **87**(18): 10255–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Tamura K, Stecher G, Peterson D, *et al.*: **MEGA6: Molecular Evolutionary Genetics Analysis version 6.0.** *Mol Biol Evol.* 2013; **30**(12): 2725–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Kouranov A, Xie L, de la Cruz J, *et al.*: **The RCSB PDB information portal for structural genomics.** *Nucleic Acids Res.* 2006; **34**(Database issue): D302–D5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Chenna R, Sugawara H, Koike T, *et al.*: **Multiple sequence alignment with the Clustal series of programs.** *Nucleic Acids Res.* 2003; **31**(13): 3497–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Webb B, Sali A: **Comparative Protein Structure Modeling Using MODELLER.** *Curr Protoc Bioinformatics.* 2014; **47**: 5.6.1–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Wu S, Zhang Y: **LOMETS: a local meta-threading-server for protein structure prediction.** *Nucleic Acids Res.* 2007; **35**(10): 3375–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Davis IW, Leaver-Fay A, Chen VB, *et al.*: **MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.** *Nucleic Acids Res.* 2007; **35**(Web Server issue): W375–W83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. DeLano WL: **The PyMOL molecular graphics system.** 2002.
[Reference Source](#)
35. Wiederstein M, Sippl MJ: **ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins.** *Nucleic Acids Res.* 2007; **35**(Web Server issue): W407–W10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Hess B, Kutzner C, van der Spoel D, *et al.*: **GROMACS 4: Algorithms for Highly Efficient, Load-balanced, and Scalable Molecular Simulation.** *J Chem Theory Comput.* 2008; **4**(3): 435–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Jorgensen WL: **OPLS force fields.** *Encyc Comput Chem.* 2002.
[Publisher Full Text](#)
38. Cheatham TE III, Miller JL, Fox T, *et al.*: **Molecular dynamics simulations on solvated biomolecular systems: the particle mesh Ewald method leads to stable trajectories of DNA, RNA, and proteins.** *J Am Chem Soc.* 1995; **117**(14): 4193–4.
[Publisher Full Text](#)
39. Hess B, Bekker H, Berendsen HJ, *et al.*: **LINCS: a linear constraint solver for molecular simulations.** *J Comput Chem.* 1997; **18**(12): 1463–72.
[Publisher Full Text](#)
40. LigPrep S: **LLC.** New York, NY. 2013.
41. Friesner RA, Banks JL, Murphy RB, *et al.*: **Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.** *J Med Chem.* 2004; **47**(7): 1739–49.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Kontoyianni M, McClellan LM, Sokol GS: **Evaluation of docking performance: comparative data on docking algorithms.** *J Med Chem.* 2004; **47**(3): 558–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Pettersen EF, Goddard TD, Huang CC, *et al.*: **UCSF Chimera—a visualization system for exploratory research and analysis.** *J Comput Chem.* 2004; **25**(13): 1605–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Jorgensen W: **QikProp, version 3.0.** Schrodinger, LLC: New York. 2006.
45. Lipinski CA: **Lead- and drug-like compounds: the rule-of-five revolution.** *Drug Discov Today Technol.* 2004; **1**(4): 337–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Cheng F, Li W, Zhou Y, *et al.*: **admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.** *J Chem Inf Model.* ACS Publications; 2012; **52**(11): 3099–105.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Sud M: **MayaChemTools.** 2010.
48. Schrödinger M: **LLC New York.** New York, 2009.
49. Laskowski RA, Swindells MB: **LigPlot+: multiple ligand-protein interaction diagrams for drug discovery.** *J Chem Inf Model.* ACS Publications; 2011; **51**(10): 2778–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Sliwoski G, Kothiwale S, Meiler J, *et al.*: **Computational methods in drug discovery.** *Pharmacol Rev.* 2014; **66**(1): 334–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

51. Duffy EM, Jorgensen WL: **Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water.** *J Am Chem Soc.* 2000; **122**(12): 2878–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Ravichandran R, Manian M: **Ribavirin therapy for Chikungunya arthritis.** *J Infect Dev Ctries.* 2008; **2**(2): 140–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Rulli NE, Rolph MS, Srikiatkachorn A, *et al.*: **Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis.** *J Infect Dis.* 2011; **204**(7): 1026–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Nagle DG, Ferreira D, Zhou YD: **Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives.** *Phytochemistry.* 2006; **67**(17): 1849–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Yamaguchi K, Honda M, Ikigai H, *et al.*: **Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).** *Antiviral Res.* 2002; **53**(1): 19–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Fassina G, Buffa A, Benelli R, *et al.*: **Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent.** *AIDS.* 2002; **16**(6): 939–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Williamson MP, McCormick TG, Nance CL, *et al.*: **Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.** *J Allergy Clin Immunol.* 2006; **118**(6): 1369–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Kim M, Kim SY, Lee HW, *et al.*: **Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate.** *Antiviral Res.* 2013; **100**(2): 460–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Ciesek S, von Hahn T, Colpitts CC, *et al.*: **The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.** *Hepatology.* 2011; **54**(6): 1947–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Calland N, Albecka A, Belouzard S, *et al.*: **(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.** *Hepatology.* 2012; **55**(3): 720–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Chen C, Qiu H, Gong J, *et al.*: **(-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.** *Arch Virol.* 2012; **157**(7): 1301–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Das S, Tanwar J, Hameed S, *et al.*: **Antimicrobial potential of epigallocatechin-3-gallate (EGCG): a green tea polyphenol.** *J Biochem Pharmacol Res.* 2014; **2**(3): 167–74.
[Reference Source](#)
63. Weber C, Sliva K, von Rhein C, *et al.*: **The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection.** *Antiviral Res.* 2015; **113**: 1–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Shekarchi M, Hajimehdipoor H, Saeidnia S, *et al.*: **Comparative study of rosmarinic acid content in some plants of Labiatae family.** *Pharmacogn Mag.* 2012; **8**(29): 37–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Peake PW, Pussell BA, Martyn P, *et al.*: **The inhibitory effect of rosmarinic acid on complement involves the C5 convertase.** *Int J Immunopharmacol.* 1991; **13**(7): 853–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Swarup V, Ghosh J, Ghosh S, *et al.*: **Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis.** *Antimicrob Agents Chemother.* 2007; **51**(9): 3367–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Won J, Hur YG, Hur EM, *et al.*: **Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner.** *Eur J Immunol.* 2003; **33**(4): 870–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Psotová J, Kolár M, Soušek J, *et al.*: **Biological activities of *Prunella vulgaris* extract.** *Phytother Res.* 2003; **17**(9): 1082–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. el-Mekkawy S, Meselhy MR, Kusumoto IT, *et al.*: **Inhibitory effects of egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase.** *Chem Pharm Bull (Tokyo).* 1995; **43**(4): 641–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Valsaraj R, Pushpangadan P, Smitt UW, *et al.*: **Antimicrobial screening of selected medicinal plants from India.** *J Ethnopharmacol.* 1997; **58**(2): 75–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Valsaraj R, Pushpangadan P, Smitt UW, *et al.*: **New anti-HIV-1, antimalarial, and antifungal compounds from *Terminalia bellerica*.** *J Nat Prod.* 1997; **60**(7): 739–42.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 18 December 2017

<https://doi.org/10.5256/f1000research.14481.r28833>

© 2017 Chattopadhyay S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Soma Chattopadhyay

Infectious Disease Biology, Institute of Life Sciences, (Autonomous Institute of Department of Biotechnology, Government of India), Bhubaneswar, Odisha, India

There are two points I want to mention. These are as follows:

Use of control in molecular docking: Docking score was used to filter the compounds as antiviral. Since docking score does not exactly estimate the binding free energy, decoys (control) should have been employed for comparisons to support the selection.

Calculation of ligand efficiency (LE): There is lack of clarity regarding author's explanation about LE. LE is usually defined as the average free energy of binding in kcal/mol per non-hydrogen atom¹. It is fine as it is in the manuscript.

References

1. Murray CW, Erlanson DA, Hopkins AL, Keserü GM, et al.: Validity of ligand efficiency metrics. *ACS Med Chem Lett.* 2014; **5** (6): 616-8 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 02 November 2017

<https://doi.org/10.5256/f1000research.13316.r27576>

© 2017 Nayak D et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Debasis Nayak

¹ Centre of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, Madhya Pradesh, India

² Centre of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, Madhya Pradesh, India

Parimal Kar

¹ Indian Institute of Technology Indore, Indore, India

² Indian Institute of Technology Indore, Indore, India

Overall comment: The article in the present form needs some revision including through checking of grammar and sentence structure. Further, I would request the authors to consider following points.

1. Authors have written that "All bonds were constrained by LINCS". This claim needs to revisit. Generally, bonds involving hydrogen atoms are restrained using *LINCS*.
2. Authors have mentioned that "In order to avoid the steric clashes, overall geometry and atomic charges were also optimized". I do not think authors have optimized the atomic charges. Rather atomic charges were obtained from the OPLS forcefield that was used in the simulations.
3. The cutoff used for PME was 0.9 Angstrom. This is very small. It should rather be 9 Angstrom.
4. Berendsen thermostat with V-rescale is not a good option for conformational sampling. A better option is Langevin dynamics.
5. Authors have written that "The system was further energy minimized without any restraints for 50,000-time steps; the steepest descent having step size of 0.01 ps". This claim needs to revisit. No time-step is required for energy minimization. Only to study dynamics, i.e., to integrate Newton's equation of motion, we need to set time-step.
6. It was not mentioned what time-step was used for the heating stage and production simulation.
7. Docking is not a good method for predicting the binding free energy. It is the least accurate method for estimating the binding free energy. However, it is a very good method for predicting the binding pose. Authors should have conducted MM-PBSA type analysis to estimate the binding free energy.
8. Figure 4 A, B, C are not required.
9. Looking at Figure 4D, one can see that for a couple of cases, longer simulation is

required. The simulation length is too small (20 ns) to investigate the dynamics of proteins. They should extend all simulations to 50 ns.

10. Figure 4: Use bigger fonts. It's not readable.

11. Calculate average RMSD and Radius of Gyration during the simulations.

12. Authors have written that "RMSF with respect to each residue....". RMSF is calculated with respect to the average structure obtained from simulations. Do you use C-alpha atoms of each residue?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Virology, immunology, imaging

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 04 Dec 2017

Sujatha Sunil

We thank the reviewers for their valuable comments and suggestions. We have considered all their suggestions and have incorporated them in the updated version of the manuscript. Point by point replies to their queries are mentioned below.

- Authors have written that "All bonds were constrained by LINCS". This claim needs to be revisited. Generally, bonds involving hydrogen atoms are restrained using *LINCS*.

Answer: Depending on the time-step applied, setting a constraint to bonds is required. The time-step depends on the highest frequency of motion within the system. If a time-step

superior to 1 fs is chosen (as in our study, we have chosen 2 fs time-step), bonds involving hydrogen will not be sampled sufficiently, thus they should be constrained. Here, we have constrained all-bonds even heavy atom-H bonds by LINCS algorithm.

- Authors have mentioned that "In order to avoid the steric clashes, overall geometry and atomic charges were also optimized". I do not think authors have optimized the atomic charges. Rather atomic charges were obtained from the OPLS forcefield that was used in the simulations.

Answer: The initial structure of the protein in optimized and the atomic charges of the protein are calculated by using the OPLS force field.

- The cutoff used for PME was 0.9 Angstrom. This is very small. It should rather be 9 Angstrom.

Answer: We apologize for the confusion. The cutoff used for PME was 0.9 nm, Angstrom has been replaced by nm in the revised MS.

- Berendsen thermostat with V-rescale is not a good option for conformational sampling. A better option is Langevin dynamics.

Answer: Berendsen thermostat was used to re-scale the velocities of particles in molecular dynamics simulations to control the simulation temperature. No conformational sampling was done in the study.

- Authors have written that "The system was further energy minimized without any restraints for 50,000-time steps; the steepest descent having step size of 0.01 ps". This claim needs to revisit. No time-step is required for energy minimization. Only to study dynamics, i.e, to integrate Newton's equation of motion, we need to set time-step.

Answer: Time step (nsteps) of 50000 i.e the maximum number of (minimization) steps to perform was provided during energy minimization. Below are the parameters provided in mdp file.

; minim.mdp - used as input into grompp to generate em.tpr

; Parameters describing what to do, when to stop and what to save

```
integrator      = steep      ; Algorithm (steep = steepest descent minimization)
emtol          = 1000.0      ; Stop minimization when the maximum force < 1000.0
                        kJ/mol/nm
emstep         = 0.01       ; Energy step size
nsteps         = 50000      ; Maximum number of (minimization) steps to perform
```

; Parameters describing how to find the neighbors of each atom and how to calculate the interactions

```
nstlist        = 1          ; Frequency to update the neighbor list and long range forces
ns_type        = grid       ; Method to determine neighbor list (simple, grid)
rlist          = 1.0        ; Cut-off for making neighbor list (short range forces)
coulombtype    = PME        ; Treatment of long range electrostatic interactions
rcoulomb       = 1.0        ; Short-range electrostatic cut-off
rvdw           = 1.0        ; Short-range Van der Waals cut-off
pbc            = xyz        ; Periodic Boundary Conditions (yes/no)
```

- It was not mentioned what time-step was used for the heating stage and production simulation.

Answer: Time-step of 20 ns was used for production simulations. Below is the parameter details provided in mdp file for production simulations.

nsteps = 10000000; 2 * 10000000 = 20000 ps , 20 ns

- Docking is not a good method for predicting the binding free energy. It is the least accurate method for estimating the binding free energy. However, it is a very good method for predicting the binding pose. Authors should have conducted MM-PBSA type analysis to estimate the binding free energy.

Answer: The study was to screen the natural compounds against CHIKV structural and non-structural proteins and identify potential inhibitors. MM-PBSA for a large number of compounds was out of the scope of the present study and hence not pursued.

- Figure 4 A, B, C are not required.

Answer: We abide by the reviewer's recommendation. The figures have been removed and changes figure is attached to the revised manuscript.

- Looking at Figure 4D, one can see that the for a couple of cases, longer simulation is required. The simulation length is too small (20 ns) to investigate the dynamics of proteins. They should extend all simulations to 50 ns.

Answer: Except for E2, every simulation has reached to a stable state as shown in the RMSD graph.

- Figure 4: Use bigger fonts. It's not readable.

Answer: We apologize for this inconvenience. The figure has been changed.

- Calculate average RMSD and Radius of Gyration during the simulations.

Answer: RMSD Average - 22.93

Radius of Gyration Average - 1.45

- Authors have written that "RMSF with respect to each residue....". RMSF is calculated with respect to the average structure obtained from simulations. Do you use C-alpha atoms of each residue?

Answer: As one can see in graph 4F, the x-axis represents the atomic positions in the trajectory after fitting to a reference frame. Yes, C-alpha atoms of each residue have been used for the analysis.

Competing Interests: No competing interests were disclosed.

Reviewer Report 12 September 2017

<https://doi.org/10.5256/f1000research.13316.r25511>

© 2017 Chattopadhyay S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Soma Chattopadhyay

¹ Infectious Disease Biology, Institute of Life Sciences, (Autonomous Institute of Department of

Biotechnology, Government of India), Bhubaneswar, Odisha, India

² Infectious Disease Biology, Institute of Life Sciences, (Autonomous Institute of Department of Biotechnology, Government of India), Bhubaneswar, Odisha, India

The present study by Jain *et al* entitled “***In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus***” was undertaken to evaluate protein-ligand interactions of all chikungunya virus (CHIKV) proteins with natural compounds from a MolBase library in order to identify potential inhibitors of CHIKV. The authors have predicted three compounds, Catechin-5-O-gallate, Rosmarinic acid and Arjungenin, to interact with CHIKV proteins; two (Catechin-5-O-gallate and Rosmarinic acid) with capsid protein, and one (Arjungenin) with the E3 which required further *in vitro* studies to test their efficacy against CHIKV.

The study is designed and executed properly, however there are few points which need to be addressed before consideration.

The points are as follows:

1. While considering drug like properties, authors have discarded molecules with 2 violations. Why did they not discard compounds with one violation?
2. No control was used in molecular docking?
3. Since the ligands were filtered mainly based on their docking score, ligand efficiency should have been taken as the criteria for selection.
4. From the final three compounds, at least catechin-5-O-gallate and rosmarinic acid are associated with poor absolute oral bioavailability. Then how they can be advanced as drug candidates?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Molecular virology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 04 Dec 2017

Sujatha Sunil

We thank the reviewer for her valuable comments and suggestions. Point by point replies to their queries are mentioned below.

- While considering drug like properties, authors have discarded molecules with 2 violations. Why did they not discard compounds with one violation?

Answer: One violation (20% violation) was kept as it showed better results for toxicity and thus was allowed.

- No control was used in molecular docking?

Answer: Docking is an *insilico* process and defined by parameters and not controls. Thus, no control was taken for the study.

- Since the ligands were filtered mainly based on their docking score, ligand efficiency should have been taken as the criteria for selection.

Answer: Ligand efficiency is calculated by the binding energy as well as h-bonds of ligand and protein and is also included in the results.

- From the final three compounds, at least catechin-5-O-gallate and rosmarinic acid are associated with poor absolute oral bioavailability. Then how they can be advanced as drug candidates?

Answer: All these compounds were positive for human intestinal absorption for oral bioavailability based on our in silico toxicity assays and thus could be advanced as drug candidates if we pursue the studies. However, to avoid confusion based on Caco permeability data that showed negative for these compounds, we have removed this data from the revised manuscript.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research